Currently Viewing:
Evidence-Based Diabetes Management April 2015
When Moving to Collaborative Care, a Challenge Is Figuring Out How to Pay for It
Mary K. Caffrey
Studies Are Showing SGLT2s Also Help Control Hypertension, Eliminate Some Side Effects
Andrew Smith
Unraveling the Mysteries and Extensive Needs of Emergency Department "Superutilizers"
Tony Hagen
What NCQA Recognition Means for Patients With Diabetes
Robert A. Gabbay, MD, PhD, FACP
A Look at the Unhealthiness of Sitting, and a Call for More Research on Its Effects
Mary K. Caffrey
TV Watching Appears Worse Than Other Forms of Sitting
Mary K. Caffrey
Study Finds Older Adults With T2DM, Comorbidities Aren't Getting Enough Treatment Time
Tony Hagen
Implementing JNC 8 Guidelines Is Generally Cost-Effective, According to NEJM Findings
Mary K. Caffrey
Weighing the Options With Bariatric Surgery: Long-Term Results Compare Risks, Health Outcomes
Surabhi Dangi-Garimella, PhD
Dietary Panel Releases Report, Cholesterol Removed From List of Nutrients to Avoid
Mary K. Caffrey
Higher-Dose Liraglutide Creates New Options to Fight Obesity, but Payment Remains a Challenge
Andrew Smith
Obesity Among Children and Teens Demands Stronger Response, Lancet Authors Find
Mary K. Caffrey
FDA Approves Toujeo, Basal Insulin Seen as Successor to Lantus
Mary K. Caffrey
Glyxambi Approved, Combo Provides Actions of SGLT2, DPP-4 Inhibitors for Patients With T2DM
Mary K. Caffrey
Currently Reading
FDA Approves Aflibercept for Diabetic Retinopathy in Patients With Diabetic Macular Edema
Mary K. Caffrey
AMA, CDC Launch Prevent Diabetes STAT to Prevent More Cases of Type 2
Mary K. Caffrey

FDA Approves Aflibercept for Diabetic Retinopathy in Patients With Diabetic Macular Edema

Mary K. Caffrey
Aflibercept, to be marketed as Eylea, received approval March 25, 2015, from FDA for treatment of diabetic retinopathy (DR) in patients with diabetic macular edema (DMA).1
 
Aflibercept is an injectable treatment for DR, which the FDA cites as the most common diabetic eye disease and a leading cause of blindness among adults ages 20 to 74 years in the United States.1 The risk of DR has increased as incidence of type 2 diabetes mellitus (T2DM) has gone up in recent decades. The number of Americans with type 1 diabetes and T2DM is about 29 million.2
 
With the approval of aflibercept, patients with DR have multiple treatment options, said Edward Cox, MD, MPH, director of the FDA’s Ofce of Antimicrobial Products at the Center for Drug Evaluation and Research. Doctors administer aibercept by injection in the eye once a month for 5 months. Then, patients receive the injections once every 2 months. Treatment is given alongside appropriate efforts to control blood sugar, blood pressure, and cholesterol.
 
The FDA approval comes after safety and efcacy were demonstrated in trials involving 679 patients in 2 studies. Participants were randomly assigned to receive aflibercept injections or macular laser photocoagulation, a laser-based treatment used to burn small areas of the retina. At week 100, those being treated with the study therapy showed signicant improvement in the severity of their DR, compared with patients who did not receive injections.
 
Common adverse events (AEs) associated with aflibercept included bleeding of the conjunctiva, eye pain, cataracts, oaters, increased eye pressure, and separation of the interior jelly of the eye from the retina. Serious AEs included eye infections and retinal detachments.
 
FDA approval follows prior designation of aflibercept as a breakthrough therapy.
REFERENCES
 
1. FDA approves new treatment for diabetic retinopathy for patients with diabetic macular edema [press release]. Silver Spring, MD: FDA Newsroom; March 25, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439838.htm
 
2. American Diabetes Association. Economic costs of diabetes in the United States. Diabetes Care. 2013;36:1033-1046.
PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up